Weight loss with glucagon-like peptide-1 receptor agonists in Bardet-Biedl syndrome

Shawg Ganawa; Smrithi Hema Santhosh; Lucy Parry; Akheel A Syed

doi:10.1111/cob.12546

Weight loss with glucagon-like peptide-1 receptor agonists in Bardet-Biedl syndrome

Shawg Ganawa
, Smrithi Hema Santhosh
, Lucy Parry
, Akheel A Syed

Division of Diabetes, Endocrinology & Gastroenterology (L5)

Salford Royal NHS Foundation Trust

Research output: Contribution to journal › Article › peer-review

Abstract

Bardet-Biedl syndrome (BBS) is a rare genetic condition, characterized by ciliary protein dysfunction, leading to multi-organ damage. People with BBS can develop early-onset severe obesity and associated problems including the metabolic syndrome, type 2 diabetes and coronary heart disease. Weight management can be challenging with the lack of effective medical therapies so far. We report a patient with BBS who underwent successful weight reduction through the use of glucagon-like peptide-1 receptor agonists.

Original language	English
Article number	e12546
Journal	Clinical Obesity
Volume	12
Issue number	5
Early online date	6 Aug 2022
DOIs	https://doi.org/10.1111/cob.12546
Publication status	Published - 1 Oct 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Laurence-Moon–Bardet-Biedl syndrome
Type 2 diabetes mellitus
glucagon-like peptide-1
hypothalamic diseases
incretins
morbid obesity
weight loss

Access to Document

10.1111/cob.12546Licence: CC BY-NC

Cite this

@article{6e5b8541c4a64695b571b3a47773a70a,

title = "Weight loss with glucagon-like peptide-1 receptor agonists in Bardet-Biedl syndrome",

abstract = "Bardet-Biedl syndrome (BBS) is a rare genetic condition, characterized by ciliary protein dysfunction, leading to multi-organ damage. People with BBS can develop early-onset severe obesity and associated problems including the metabolic syndrome, type 2 diabetes and coronary heart disease. Weight management can be challenging with the lack of effective medical therapies so far. We report a patient with BBS who underwent successful weight reduction through the use of glucagon-like peptide-1 receptor agonists.",

keywords = "Laurence-Moon–Bardet-Biedl syndrome, Type 2 diabetes mellitus, glucagon-like peptide-1, hypothalamic diseases, incretins, morbid obesity, weight loss",

author = "Shawg Ganawa and Santhosh, \{Smrithi Hema\} and Lucy Parry and Syed, \{Akheel A\}",

note = "Funding Information: We thank our patient for giving informed, signed consent to publication. We thank the Clinical Endocrinology Trust and the Society for Endocrinology for the award of best presentation in the Disorders of Appetite and Weight workshop at the SfE Clinical Update Meeting 2022, Birmingham, UK (25–27 April 2022); DOI: 10.1530/endoabs.82.WG1. Publisher Copyright: {\textcopyright} 2022 The Authors. Clinical Obesity published by John Wiley \& Sons Ltd on behalf of World Obesity Federation.",

year = "2022",

month = oct,

day = "1",

doi = "10.1111/cob.12546",

language = "English",

volume = "12",

journal = "Clinical Obesity",

issn = "1758-8111",

publisher = "John Wiley \& Sons Ltd",

number = "5",

}

TY - JOUR

T1 - Weight loss with glucagon-like peptide-1 receptor agonists in Bardet-Biedl syndrome

AU - Ganawa, Shawg

AU - Santhosh, Smrithi Hema

AU - Parry, Lucy

AU - Syed, Akheel A

N1 - Funding Information: We thank our patient for giving informed, signed consent to publication. We thank the Clinical Endocrinology Trust and the Society for Endocrinology for the award of best presentation in the Disorders of Appetite and Weight workshop at the SfE Clinical Update Meeting 2022, Birmingham, UK (25–27 April 2022); DOI: 10.1530/endoabs.82.WG1. Publisher Copyright: © 2022 The Authors. Clinical Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.

PY - 2022/10/1

Y1 - 2022/10/1

N2 - Bardet-Biedl syndrome (BBS) is a rare genetic condition, characterized by ciliary protein dysfunction, leading to multi-organ damage. People with BBS can develop early-onset severe obesity and associated problems including the metabolic syndrome, type 2 diabetes and coronary heart disease. Weight management can be challenging with the lack of effective medical therapies so far. We report a patient with BBS who underwent successful weight reduction through the use of glucagon-like peptide-1 receptor agonists.

AB - Bardet-Biedl syndrome (BBS) is a rare genetic condition, characterized by ciliary protein dysfunction, leading to multi-organ damage. People with BBS can develop early-onset severe obesity and associated problems including the metabolic syndrome, type 2 diabetes and coronary heart disease. Weight management can be challenging with the lack of effective medical therapies so far. We report a patient with BBS who underwent successful weight reduction through the use of glucagon-like peptide-1 receptor agonists.

KW - Laurence-Moon–Bardet-Biedl syndrome

KW - Type 2 diabetes mellitus

KW - glucagon-like peptide-1

KW - hypothalamic diseases

KW - incretins

KW - morbid obesity

KW - weight loss

U2 - 10.1111/cob.12546

DO - 10.1111/cob.12546

M3 - Article

C2 - 35932204

SN - 1758-8111

VL - 12

JO - Clinical Obesity

JF - Clinical Obesity

IS - 5

M1 - e12546

ER -

Weight loss with glucagon-like peptide-1 receptor agonists in Bardet-Biedl syndrome

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this